Welcome to the Nature Reviews Immunology web focus on translational immunology
- a selection of recently published Reviews, Perspectives and Research Highlights on this topic. Additional articles are available in the associated NPG library.
From the Editors
Research Highlights & News
Immunotherapy
Gene Therapy
Phoxing a myeloid-cell genetic defect
Karen Honey
doi: 10.1038/nri1855
Nature Reviews Immunology 6, 338 (2006)
Immunotherapy
In the News
Reviews
Potent antibody therapeutics by design
Paul J. Carter
doi: 10.1038/nri1837
Nature Reviews Immunology 6, 343-357 (2006)
The use of antibodies as therapeutic agents is a big business, with 18 now approved for use in the United States. How they are generated and optimized to increase efficacy and safety is the focus of extensive research efforts, which are reviewed here.
Statin therapy and autoimmune disease: from protein prenylation to immunomodulation
John Greenwood, Lawrence Steinman and Scott S. Zamvil
doi: 10.1038/nri1839
Nature Reviews Immunology 6, 358-370 (2006)
Statins are best known as cholesterol-lowering drugs but increasing evidence indicates that they might be an effective treatment for autoimmune disease. Their ability to inhibit post-translational protein prenylation could be key to their immunomodulatory effects.
Microbicides and other topical strategies to prevent vaginal transmission of HIV
Michael M. Lederman, Robin E. Offord and Oliver Hartley
doi: 10.1038/nri1848
Nature Reviews Immunology 6, 371-382 (2006)
With the search for an HIV vaccine still ongoing, attention is turning towards developing topical prevention strategies that prevent HIV transmission. This Review describes the rationale behind the choice of targets for such strategies and how their clinical development is progressing.
Adoptive immunotherapy for cancer: building on success
Luca Gattinoni, Daniel J. Powell, Jr., Steven A. Rosenberg and Nicholas P. Restifo
doi: 10.1038/nri1842
Nature Reviews Immunology 6, 383-393 (2006)
This Review discusses recent studies that have identified ways to increase the antitumour response of autologous tumour-reactive cells adoptively transferred to individuals with cancer, such as the use of lymphodepleting regimens before adoptive cell transfer.
B-cell targeting in rheumatoid arthritis and other autoimmune diseases
Jonathan C. W. Edwards and Geraldine Cambridge
doi: 10.1038/nri1838
Nature Reviews Immunology 6, 394-403 (2006)
Clinical trials of reagents that target B cells in individuals with autoimmune disease, in particular rheumatoid arthritis, have yielded highly promising results. Might such an approach bring us closer to the goal of re-establishing immune tolerance in these individuals?
Immunology and immunotherapy of Alzheimer's disease
Howard L. Weiner and Dan Frenkel
doi: 10.1038/nri1843
Nature Reviews Immunology 6, 404-416 (2006)
Although the discontinuation of a clinical trial of amyloid-β vaccination of subjects with Alzheimer�s disease led us to reassess the use of immune-based therapy for this disease, subsequent work involving antibody and cell-based therapies look promising.
Perspective
Opinion
Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases
Giuseppe Pantaleo and Alexandre Harari
doi: 10.1038/nri1840
Nature Reviews Immunology 6, 417-424 (2006)
How does a T-cell response to viral infection inform us of the state of the disease? Patterns of cytokine production by T cells could hold the key and might be useful markers for monitoring virus-associated disease in the clinic.
© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.
